Quantcast

Vaxart to Present at Global Medical Meetings in April

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced participation in two upcoming
global medical meetings in April.

Vaxart will present the following:

  • Poster presenting potential new immune correlates of protection for
    influenza observed in the Phase 2 challenge study of its H1 influenza
    oral tablet vaccine at the upcoming International Society for
    Influenza and other Respiratory Virus Diseases’ (ISIRV) Immunological
    Assays and Correlates of Protection for Next Generation Influenza
    Vaccines conference, taking place from March 31-April 2, 2019 in
    Siena, Italy
  • New scientific data supporting the importance of mucosal IgA to
    protect against influenza and a summary of data from the Phase 2
    challenge study of its H1 influenza oral tablet vaccine at the
    upcoming Influenza Vaccines for the World (IVW) 2019, taking place
    from April 2-4, 2019 in Edinburgh, Scotland

Details of the presentations are as follows:

Immunological Assays and Correlates of Protection for Next Generation
Influenza Vaccines Conference

Poster Title: Cell-Mediated Immunity Correlates of Protection
in an Influenza Challenge Study following Vaccination via Oral Tablet in
Humans

Date & Time: Monday, April 1, 2019 at 5:30 PM
CET
Authors: Keith Gottlieb, et al.
Session: Poster
Presentation

Influenza Vaccines for the World 2019

Presentation Title: Recent progress in novel, cross-reactive
and universal influenza vaccines

Date & Time: Tuesday,
April 2, 2019 at 3:40 PM GMT
Authors: Sean Tucker
Session:
Session 5: Influenza Vaccines Developments II – Antigen Design and
Characterization

Presentation Title: IgA is critical for protection against
influenza following mucosal delivery

Date & Time: Wednesday,
April 3, 2019 at 12:30 PM GMT
Authors: Nikita Kolhatkar
Session:
Session 7: Influenza vaccines developments in mechanisms of action &
correlates of protection

The Phase 2 study was completed with support from Biomedical Advanced
Research and Development Authority (BARDA). Vaxart received a $13.9
million contract from BARDA in September 2015 to support the advanced
development of more effective influenza vaccines to ultimately improve
seasonal and pandemic influenza preparedness. The contract was increased
to $15.7 million in 2017.

The project has been funded in whole or in part with federal funds from
the Department of Health and Human Services’ Office of the Assistant
Secretary for Preparedness and Response; Biomedical Advanced Research
and Development Authority under Contract No. HHSO100201500034C.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may also be useful for the treatment of chronic viral
infections and cancer. Vaxart’s vaccines are administered using a
convenient room temperature-stable tablet, rather than by injection.
Vaxart believes that tableted vaccines are easier to distribute and
administer than injectable vaccines and have the potential to
significantly increase vaccination rates. Vaxart’s development programs
include oral tablet vaccines that are designed to protect against
norovirus, seasonal influenza and respiratory syncytial virus (RSV), as
well as a therapeutic vaccine for human papillomavirus (HPV). For more
information, please visit www.vaxart.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential,” “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates and clinical results and trial
data; and Vaxart’s expectations with respect to the advantages it
believes its oral vaccine platform can offer over injectable
alternatives, particularly for mucosal pathogens such as norovirus, flu
and RSV. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various factors could cause
actual results or events to differ materially from these forward-looking
statements, including Vaxart’s ability to raise sufficient capital to
fund the continued development of its product candidates and complete
its planned studies and trials, that Vaxart’s product candidates may not
be approved by the FDA or non-U.S. regulatory authorities; that, even if
approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product
candidates may not achieve broad market acceptance; that Vaxart may
experience manufacturing issues and delays; and other risks described in
the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update any
forward-looking statements, except as required by law.

Contacts

Carl Mauch
Stern Investor Relations
212-362-1200
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.